3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
21
Neoplasms
6
Carcinoma, Hepatocellular
5
Stomach Neoplasms
4
Recurrence
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Cancer
4
Uveal Melanoma
3
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Liver Neoplasms
3
Colonic Neoplasms
3
Rectal Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasm Metastasis
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Hodgkin Disease
2
Hematologic Neoplasms
2
Glioma
2
Glioblastoma
2
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Basal Cell
2
Brain Neoplasms
2
Interventions
padeliporfin
5
Lycopene
3
pembrolizumab
2
darolutamide
2
Vitamin E
2
Tea
2
Selenium
2
Cholecalciferol
2
relatlimab
1
palladium-bacteriopheophorbide
1
olaparib
1
gedatolisib
1
enfortumab vedotin
1
Therapeutics
1
Surveys and Questionnaires
1
Sugars
1
Radiation Dose Hypofractionation
1
Pluvicto
1
Nivolumab
1
Mitomycin
1
Intraoperative Neurophysiological Monitoring
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
CP protocol
1
Blood Specimen Collection
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Male Urogenital Diseases
×
relatlimab
×
Clear all
NCT06237920
2025-09-03
TURANDORELA
The Netherlands Cancer Institute
Phase 2
Recruiting
90 enrolled